DURHAM,
N.C., May 15, 2024 /PRNewswire/ -- Tiamat
Sciences Corporation, a pioneering plant-based reagent company,
proudly announces a significant milestone in the realm of mRNA
enzyme production. Tiamat Sciences has successfully expressed T7
polymerase, a crucial enzyme for mRNA vaccine synthesis, within its
plant system with the goal of producing the enzyme for use in mRNA
production processes. This achievement marks a leap forward in the
quest for more efficient, sustainable, and scalable methods for
vaccine development.
The production of T7 polymerase is crucial to mRNA vaccine
production due to its role in synthesizing messenger RNA (mRNA),
which is a key component of mRNA vaccines. mRNA vaccines work by
delivering mRNA molecules encoding specific antigens into the body.
Once inside cells, these mRNA molecules instruct the cells to
produce the antigen proteins, triggering an immune response that
leads to the development of immunity against the targeted
pathogen.
Tiamat Sciences' achievement demonstrates the efficacy of
harnessing plant-based systems to produce essential reagents.
This achievement holds profound implications for the
pharmaceutical industry, particularly in the context of pandemic
preparedness and rapid vaccine development. The ability to produce
critical enzymes like T7 polymerase in plant systems offers
unparalleled flexibility, scalability, and cost-effectiveness,
paving the way for the accelerated production of mRNA vaccines on a
global scale.
"We are thrilled to announce this milestone achievement that
demonstrates the diversity of reagents that we can make." said
France-Emmanuelle Adil, Co-Founder
and CEO of Tiamat Sciences. "By successfully expressing T7
polymerase in plants, we have achieved a significant milestone that
underscores the power of plant-based biotechnology to drive
innovation and address critical challenges in healthcare."
Recently, Tiamat Sciences has made another notable advancement
by successfully expressing human Fibroblast Growth Factor 2 (hFGF2)
at a yield exceeding 20mg/kg biomass. This breakthrough enables
further optimization to achieve even higher yields, meeting the
demands of the Regenerative Medicine sector for affordable Cell
& Gene therapies.
Tiamat Sciences emphasizes that while it doesn't manufacture
vaccines, its reagents play a vital role in fueling innovation in
the healthcare and pharmaceutical sectors. By providing essential
tools and technologies, Tiamat Sciences enables pharmaceutical
companies to accelerate the development and production of
life-saving treatments.
Tiamat Sciences is actively seeking strategic co-development
partnerships with to further advance this technology and expedite
the commercialization of plant-based reagents for vaccine
production. With a commitment to sustainability, innovation, and
global health, Tiamat Sciences aims to revolutionize the way
essential biomolecules are produced, ensuring equitable access to
life-saving treatments for people around the world.
For more information about Tiamat Sciences and partnership
opportunities, please visit tiamat-sciences.com.
About Tiamat Sciences:
Tiamat Sciences is a plant-based platform and product life
sciences company that is revolutionizing the production of
reagents. Leveraging cutting-edge biotechnology, Tiamat Sciences
enables their partners to create innovative therapies while also
lowering their material cost, compressing development timelines,
and decarbonizing the supply chain.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/innovative-plant-based-reagent-start-up-achieves-breakthrough-in-expression-of-mrna-enzyme-for-use-as-a-reagent-in-vaccine-production-302145254.html
SOURCE Tiamat Sciences